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Abstract
Background: Dendritic cells (DCs) are the most potent antigen-presenting cells in the mammalian immune system. In the
skin, epidermal Langerhans cells (LCs) and dermal dendritic cells (DDCs) survey for invasive pathogens and present antigens
to T cells after migration to the cutaneous lymph nodes (LNs). So far, functional and phenotypic differences between these
two DC subsets remain unclear due to lack of markers to identify DDCs.
Methodology/Principal Findings: In the present report, we demonstrated that macrophage galactose-type C-type lectin
(MGL) 2 was exclusively expressed in the DDC subset in the skin-to-LN immune system. In the skin, MGL2 was expressed on
the majority (about 88%) of MHCII
+CD11c
+ cells in the dermis. In the cutaneous LN, MGL2 expression was restricted to
B220
2CD8a
loCD11b
+CD11c
+MHCII
hi tissue-derived DC. MGL2
+DDC migrated from the dermis into the draining LNs within
24 h after skin sensitization with FITC. Distinct from LCs, MGL2
+DDCs localized near the high endothelial venules in the
outer T cell cortex. In FITC-induced contact hypersensitivity (CHS), adoptive transfer of FITC
+MGL2
+DDCs, but not
FITC
+MGL2
2DCs into naive mice resulted in the induction of FITC-specific ear swelling, indicating that DDCs played a key
role in initiation of immune responses in the skin.
Conclusions/Significance: These results demonstrated the availability of MGL2 as a novel marker for DDCs and suggested
the contribution of MGL2
+ DDCs for initiating CHS.
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Introduction
Dendritic cells (DCs) are highly potent antigen presenting cells
(APCs) capable of initiating immune responses. In the skin,
Langerhans cells (LCs) in the epidermis form a network for
surveillance for antigens. LCs are known to express Langerin, a C-
type lectin which contributes to formation of Birbeck granules [1–
3]. Besides the LCs, normal skin contains another type of DCs in
the dermis [4]. In the initiation phase of immune responses in the
skin, both the LCs and dermal DCs (DDCs) are thought to migrate
into the skin-draining lymph nodes (LNs) to present antigens to T
cells [5,6]. However, functional and phenotypic differences
between LCs and DDCs are still controversial.
In spite of their clear definition of DDCs based on their
localization in the skin, there is no straightforward way to detect
DDCs in murine LNs due to the lack of DDC-specific marker,
making it complicated to correctly understand their roles in
immune responses in comparison to LCs. In LNs, at least five
different subsets of DCs have been identified in mice based on
their surface markers, two of which are restricted to the skin-
draining and mesenteric LNs, and are therefore thought to
correspond to LCs or DDCs in the skin [7–14]. In these previous
studies, however, difference between LCs and DDCs in the skin-
draining LNs was ambiguous because the distinction was based on
the differential intensity of markers such as CD8a, CD11b, and
CD205 [10].
Contact hypersensitivity (CHS) is one of the well-characterized
immune responses in the skin. Although LCs have long been
believed to be responsible for CHS initiation as APCs [15,16],
recent studies on in vivo LC-depletion in mice reported a significant
CHS response, indicating dispensability of LCs and contribution
of DDCs to the CHS induction [12,17,18]. However, the
interpretation of their results should be much more complicated
after the recent discovery of Langerin
+DDCs [19–21]. Thus, a role
for DDCs in the induction of immune responses was only
indirectly suggested by depleting LCs or by painting of a
fluorescent dye in bone marrow-chimeric mice [22]. The lack of
a direct proof is at least in part due to the absence of specific
markers for DDCs.
Macrophage (MØ) galactose-type C-type lectins (MGLs) are a
family of type II C-type lectins expressed in connective tissue MØs
and in bone marrow-derived DCs [23,24]. The number of
MGL
+cells, originally thought to be MØs, in the draining LNs was
previously shown to correlate to the severity of CHS following
epicutaneous application of a hapten, fluorescein isothiocyanate
(FITC) [25]. We recently found that there are two MGL genes in
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known Mgl as Mgl1 [26]. Although analysis of mRNA expressions
in mouse tissues and cell lines suggested that the Mgl2 gene was
expressed in a cell population similar to that expressing MGL1
[26], a detailed characterization of cells expressing MGL2 was not
clear, since MGL-specific monoclonal antibodies (mAbs) used
previously turned out to recognize a common epitope for MGL1
and MGL2 (mAb LOM-14 and mAb ER-MP23) except for mAb
LOM-8.7 specific for MGL1 [26–28].
Development of mAb specific for MGL2, URA-1, enabled us to
characterize the cell populations expressing MGL2 in the skin and
the cutaneous LNs. MGL2 was found to be highly restricted to
DDCs in the skin and the LNs. We observed rapid accumulation
of MGL2
+DDCs, which localized in the outer T cell cortex closely
associated with the high endothelial venule (HEV)-related reticular
structure, in the draining LNs within 24 h of sensitization with
FITC. These cells were sufficient to induce a CHS response when
adoptively transferred to naı ¨ve mice. In contrast, adoptive transfer
of FITC
+MGL2
2DCs isolated from the draining LNs 4 days after
sensitization did not induce CHS. These results provide a concrete
evidence that hapten-incorporated DDCs are sufficient to induce
CHS in vivo.
Materials and Methods
Mice and FITC sensitization
Five- to seven-week-old specific pathogen-free Balb/c mice of
both sexes were purchased from Charles River Japan (Yokohama,
Japan) or SLC Japan (Hamamatsu, Japan). They were fed and
housed according to the guidelines of the Ministry of Education,
Culture, Sports, Science and Technology of Japan. The protocols
of the animal experiments were approved by the Animal
Experiment Committee of the Graduate School of Pharmaceutical
Sciences of the University of Tokyo guided by the Bioscience
committee of the University of Tokyo. In the CHS experiments,
mice were painted with 0.5% FITC (w/v) in a 1:1 mixture of
acetone and dibutylphthalate (ADBP) on the shaved brachial
(100 ml/site) and/or abdominal (100 ml/site) skin.
Histochemistry
All mAbs used in the present study were purchased from
eBioscience (San Diego, CA) unless otherwise indicated. mAbs to
MGL1 (clone LOM-8.7) and MGL2 (clone URA-1) were purified
and labeled as previously described [29,30]. The details in the
mAb URA-1 will be described elsewhere (Denda-Nagai et al,
manuscript in preparation). In fluorescent microscopy, frozen
sections were incubated with mAbs LOM-8.7, URA-1, LOM-14,
MECA-79 (BD Biosciences, Franklin Lakes, NJ), ER-TR7
(Serotec, Oxford, UK) or anti-Langerin (eBioRMUL.2) followed
by treatment with Cy5-conjugated mouse anti-rat IgG (H+L)
(Jackson ImmunoResearch, West Grove, PA). Propidium iodide
was used for the counter-staining. For double staining experi-
ments, samples were sequentially treated with biotinylated mAbs
LOM-8.7, URA-1, anti-CD11b (M1/70), or anti-F4/80 (BM8).
The biotinylated mAbs were visualized by Alexa Fluor 568-
conjugated streptavidin (Invitrogen, Carlsbad, CA) and were
observed with a confocal microscope (MRC-1024, Bio-Rad,
Hercules, CA). In some experiments, biotinylated mAbs LOM-
14, anti-CD11c (N418), anti-B220 (RA3-6B2) and anti-MHCII
(M5/114.15.2) were used in combination with alkaline phospha-
tase-conjugated streptavidin (Vector Laboratories, Burlingame,
CA) developed by Histomark Red (Kirkegaard & Perry,
Geithersburg, MD) and observed under a light microscope
(TMD-300, Nikon).
Flow cytometry
LNs were teased and digested in RPMI1640 medium
supplemented with 10% fetal calf serum, 2 mg/ml collagenase
(Wako Pure Chemical, Osaka, Japan) and 50 mg/ml DNaseI
(Roche, Basel, Switzerland) for 30 min at 37uC. Skin pelt after
removing the adipose was incubated with 0.8% trypsin (BD
Biosciences) in PBS. The epidermis and the dermis were then
separately digested with 6 mg/ml collagenase and, in the case of
the dermis, with additional 2 mg/ml hyaluronidase (MP Biome-
dicals, Irvine, CA). To stain intracellular molecules, cells were
permeabilized with FIX&PERM (An Der Grub Bioresearch,
Kaumberg, Austria). In some cases, CD11c
+cells were isolated by
magnetic cell sorting (MACS) (Miltenyi Biotec, Gladbach,
Germany) according to the manufacturer’s protocol. The ratio
of CD11c
+cells in the purified fraction was over 95%, which was
confirmed by phycoerythrin (PE)-labeled anti-CD11c mAb in each
experiment. The cells were incubated with mixtures of biotinylated
mAb LOM-8.7 or mAb URA-1 and PE-labeled mAbs against
CD4 (GK1.5), CD8a (53-6.7), CD11b, CD11c, CD86 (GL1),
B220, F4/80, Ly6G (RB6-8C5), MHCII or CD40 (1C10,
BioLegend, San Diego, CA) followed by treatment with strepta-
vidin-conjugated allophycocyanin (eBioscience). In some experi-
ments, FITC-conjugated anti-CD11c mAb, Alexa Fluor 488-
conjugated anti-Langerin, PE-conjugated anti-CD205 (NLDC-
145, Miltenyi) and allophycocyanin-labeled mAb URA-1 were
used. Dead cells were stained and gated out with 7-aminoactino-
mycin D (eBioscience). The cells were analyzed by FACSAria cell
sorter with FACSDiVa software (BD Biosciences).
In vivo migration of DC
Mice were shaved in the side-abdominal skin (approximately
262c m
2) and painted with 50 ml of ADBP. The cell suspensions
from the site of skin irritation and the draining inguinal LNs were
analyzed by flow cytometry. In the pertussis toxin (PTX)
treatment, mice were injected with 0.5 mg of PTX (ListBiological
Laboratories, Campbell, CA) into the front footpad, then 30 mlo f
FITC/ADBP solution was painted on the tip of the same footpad.
The draining brachial and axillary LNs 24 h after sensitization
were excised to prepare the cell suspensions.
Adoptive transfer and elicitation of CHS
CD11c
+cells were isolated by MACS from the draining LN 24 h
or 4days after sensitization, then FITC
+ MGL2
+cells or FITC
+
MGL2
2cells were sorted by FACSAria cell sorter. The sorted cells
(7.5610
4 or 5610
4 cells/recipient) were resuspended in 30 ml each
of Hanks’ balanced salt solutions and injected into the footpad of
naive mice. The same number of cells fixed with 2.5% (v/v)
glutaraldehyde was used as a control. Six days later, the recipient
mice were painted with 20 ml of 0.5% FITC/ADBP on the dorsal
right ear skin. The left ear was treated with the vehicle alone as a
control. As negative and positive controls for sensitization, naive
mice and mice painted with 200 ml of 0.5% FITC/ADBP 6 days
prior to sensitization were used. The FITC-specific ear swelling was
defined as follows: (right ear thickness at 24 h after elicitation - right
ear thickness before elicitation)-(left ear thickness at 24 h after
elicitation-left ear thickness before elicitation).
Statistic Analysis
All experiments were independently performed at least three
times, except the glutaraldehyde fixation and FITC
+MGL2
2DC
controls in the adoptive transfer experiments, which were
independently performed twice. Data were compared by two-sided
Student’s t test and presented as mean6standard deviation (SD).
MGL2 on Dermal Dendritic Cells
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Expression of MGL1and 2 in a major DDC subset in the
skin was shown by antibody bindings
Bindings and localization of mAb LOM-8.7(anti-MGL1) and
mAb URA-1(anti-MGL2) in skin of naı ¨ve mice were immunohis-
tochemically examined. Binding sites of these mAbs showed
similar distribution patterns within the dermis, though more
MGL1
+cells appeared to be present than MGL2
+cells (Figure 1).
These mAbs did not bind any cells in the epidermis, indicating the
absence of MGL1 or 2 in epidermal LCs (Figure 1A) as shown in
our previous work with a MGL1/2 cross-reactive mAb (23). By
flow cytometric analysis of the dermal and epidermal cell
suspensions, cells bound by mAb LOM-8.7 or mAb URA-1 were
observed only in cell suspensions from the dermis (Figure 1B).
Binding of mAb URA-1 was observed with the cells, to which
mAb LOM-8.7 and mAb specific for MHCII strongly bound
(Figure 1B). Higher levels of MHCII were found on the cells
reactive to mAb URA-1 compared to the LCs from the epidermis,
suggesting that MGL2
+ cells potentially function as APCs
(Figure 1B). Intracellular CD11c was also determined after
permeabilization, because the cell surface CD11c is known to be
cleaved by trypsinization [31]. The expression of MGL2 was
shown to be restricted to ,88% of CD11c
+MHCII
hi DDCs
(Figure 1C). The MGL2
2CD11c
+MHCII
hi cells (1267% in
dermal CD11c
+MHCII
+cells) may represent migrating LCs,
undifferentiated DDC precursors, or another DDC subset [1,19–
21,32].
MGL2
+DCs migrate to the cutaneous LNs after FITC
sensitization
We subsequently examined bindings of mAbs specific for
MGL1 or MGL2 to the skin-draining LNs. Distribution of binding
sites for mAb LOM-8.7 was mainly observed in the medullary and
subcapsular sinuses, which was a similar distribution seen by
MGL1/2-cross reactive mAb LOM-14 previously (Figure 2A).
Distribution of binding sites of mAb URA-1 was restricted to the
cortical areas (Figure 2A). As previously shown by the use of mAb
LOM-14 [25], a larger number of cells reactive with mAb URA-1
were observed in the T cell cortex after FITC sensitization
(Figure 2A). Binding of mAb LOM-8.7 specific for MGL1 was
found both in the sinuses and in the cortex. The distributions of
cells reactive with these mAbs were compared with distributions of
cells reactive with mAbs to other MØ/DC markers in the draining
LNs 4 h after FITC sensitization. Immunohistochemical staining
with mAb LOM-8.7 indicated that the level of MGL1 expression
of the cells in the cortical area was lower than that of the cells in
the sinusoidal area (Fig, 2A and B). The MGL1 distribution in the
sinusoidal areas overlapped with that of CD11b and F4/80 and
these cells probably represent sinusoidal MØs (Figure 2B)
consistent with our previous reports [23,33]. Colocalization of
CD11b or F4/80 with MGL1 in relatively large cells in the
medullary sinus was further confirmed by confocal microscopy
(Figure 2C). In the cortex, distribution of cells reactive with mAb
LOM-8.7 and those with mAb URA-1 was similar to that of cells
bound by anti-MHCII and anti-CD11c mAbs, indicating that
MGL1
+/MGL2
+ cells represent DCs distributing within the T cell
areas (Figure 2B). While cells bound by anti-MHCII and anti-
CD11c mAbs scattered throughout the cortex, binding of mAb
URA-1 was highly restricted to the cells in outer region within the
cortex, suggesting that MGL2
+ cells represented a distinct
population in DC subsets. Unlike the binding sites of mAb
LOM-8.7, the binding sites of mAb URA-1 did not overlap with
CD11b or F4/80 in the medullary sinus. In contrast, overlap of
mAb URA-1 binding with these markers was observed in the
cortex where the majority of MGL2
+ cells localized (Figure 2C).
These results indicate that MGL2 is expressed in a relatively
homogenous population whereas MGL1 associates with several
populations including the MGL2
+ cells in the skin-draining LN.
Flow cytometric analysis indicated that mAb URA-1
binding was limited to CD8a
loCD11b
+CD205
int DDCs in
the subcutaneous LNs
The surface phenotype of cells reactive with anti-MGL1 or anti-
MGL2 mAbs in the skin-draining LNs was further examined by
flow cytometry. As suggested by the results of immunohistochem-
ical examinations, the mAb LOM-8.7-binding MGL1
+ population
was found to contain several subpopulations, while mAb URA-1-
binding MGL2
+ population represented a homogenous group of
cells (Figure 3A). The MGL1
+ population contained a B220
+,
CD11b
2, CD11c
int, MHCII
lo, CD86
2, Ly6G
+ subpopulation,
while the MGL2
+ population did not (Figure 3A). Double labeling
analysis showed that all MGL2
+cells were reactive with mAb
LOM-8.7 and that a distinct population was reactive with mAb
LOM-8.7 but not with mAb URA-1 (Figure 3B).
The MGL1
+MGL2
2 population, which was B220
+,C D 1 1 c
int,
Ly6G
+ and MHCII
lo, apparently corresponded to the previously
published phenotype of plasmacytoid DCs (pDCs) [8,34]. This was
confirmed by the fact that pDCs (B220
+CD11c
int) only expressed
MGL1 but not MGL2 (Figure 3C). Although we clearly observed
MGL1
+MGL2
2MØs by immunohistochemistry (Figure 2C), we
could not detect any F4/80
hi typical MØs by flow cytometry
probably due to difficulties in isolating MØs from the LNs as single
cell suspensions. The conventional DC (cDC) fraction in the
MGL1
+cell population showed a similar phenotype to the MGL2
+
population, which was B220
2,C D 8 a
lo,C D 1 1 b
hi, CD11c
+,
MHCII
hi,C D 8 6
+,L y 6 G
2 and F4/80
+ (Figure 3A). This surface
phenotype indicated that the MGL1
+MGL2
+ population represent-
ed a subset of interstitial DC according to previous reports [7,9,10].
Therefore, the MGL1
+ population was likely to contain interstitial
DCs, pDCs and MØs and the MGL2
+ population consisted of
interstitial DCs, which also expressed MGL1. The surface
phenotype of MGL2
+DDCs in the skin (Figure 1) and in the LNs
(Figures 2 and 3) was similar in C57BL/6 mice (data not shown).
Considering a previous report that interstitial DCs in the skin-
draining LNs were derived from the skin [11], the expression of
Langerin in MGL2
+DCs was examined to judge whether they
were derived from LCs or DDCs. The MGL2
+ population was
Langerin
2CD205
int by the intracellular Langerin staining
(Figure 3D), indicating that they represented a population derived
from DDCs. Only a minor subset of CD11c
+ DCs seemed to be
positive with both MGL2 and Langerin, perhaps corresponded to
the Langerin
+DDCs [19–21] reported previously as a minor DC
subset [28]. The number of MGL2
+ DCs in the skin and in the
corresponding draining LNs was compared before and after
irritation of the skin with ADBP. MGL2
+ DCs decreased in the
skin and increased in the draining LNs concomitantly after
irritation with ADBP (Figure 3E), suggesting that the MGL2
+
population migrated from the dermis to the draining LN. In
addition, the expression level of MGL2 apparently remained
stable after migration (Figure 3E).
The migration of skin-resident DCs to the subcutaneous LNs was
known to be chemokine- and its downstream G protein-dependent
and therefore blocked by G protein inhibitor PTX. As shown in
Figure 3E, increase in the number of MGL2+ cells was not observed
inthe draining LNwhenPTX wass.c.injectedinto the footpad prior
to the administration of FITC/ADBP. The results strongly suggest
that migration of MGL2
+ DDCs is chemokine-dependent. Further-
MGL2 on Dermal Dendritic Cells
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identify DDCs in the skin-to-LN immune system.
MGL2
+DDCs express high levels of costimulatory
molecules even under nonstimulated conditions
To further characterize the MGL2
+DDCs, we compared the
surface phenotypes of these cells with MGL2
2DCs in LNs. Naive
CD11c
+DCs isolated by MACS were separated into two groups
based on their expression of MGL2. The expression levels of
CD8a, CD11c, CD40, and CD86 were examined in these two
populations. As previously described [9], the total CD11c
+ DCs
were further divided into three groups by the expression levels of
CD11c and CD40 (population I: CD40
intCD11c
hi, population II:
CD11c
intCD40
hi,and populationIII:CD11c
hiCD40
hi)(Figure4A).
MGL2
+ DDCs were highly homogeneous and consisted of only
CD11c
hiCD8a
loCD40
hiCD86
hi cells, which corresponded to
Figure 1. Expression of MGL1 and MGL2 in a DDC subset in skins of naive mice. (A) Binding of anti-MGL1 and anti-MGL2 mAbs to
cryosections of skin (blue in each panel). The dashed line in the control panel (Ctrl. IgG) indicates the dermal-epidermal junction. Nuclei are shown in
red. Scale bar, 100 mm. E: epidermis, D: dermis, F: hair follicle. (B) Surface staining by anti-MGL1 and anti-MGL2 mAbs of epidermal and dermal cell
suspensions. (C) Intracellular staining of CD11c and surface staining of MHCII and MGL2 in the dermal cell suspension. Virtually all MGL2
+ cells
expressed CD11c. The proportion of MGL2
+ cells in MHCII
hi CD11c
+ DDC (cells in the rectangular gate) was 88.566.8%.
doi:10.1371/journal.pone.0005619.g001
MGL2 on Dermal Dendritic Cells
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expression levels of CD40 and CD86 in MGL2
+DDCs indicated
that these cells were matured by definition at the steady state as
demonstrated previously for migratory CD11c
+MHCII
hi DCs
(Figure 4A) [35]. It was previously suggested that CD11c
hiCD40
hi
DCs (population III) were derived from epidermal LCs because of
the presence of cells containing Birbeck granules, though their
frequency seemed to be small [9]. However, only a few MGL2
2
cells belonged to population III, suggesting that most cells in
population III were DDCs (Figure 4A). Interestingly, the
expression of both CD40 and CD86 on MGL2
+ DDCs was
higher in the draining LNs 24 h after FITC sensitization than in
the naı ¨ve LNs (Figure 4B). Because expression levels of MGL2 on
DDCs were not affected by migration, and MGL2
+DDCs in the
non-sensitized LNs are likely to represent a ‘‘steady-state
migratory’’ DC population (Figure 3E), these results indicated
that newly-migrated ‘‘sensitization-induced migratory’’ DDCs
express higher levels of co-stimulatory molecules than
MGL2
+DDCs that were already in the LNs by steady-state
migration at the time of sensitization, as was suggested in the
previous report [35]. These results suggest that MGL2
+DDCs
have a ‘‘semimature’’ phenotype even under steady state
conditions and further upregulate their co-stimulatory molecule
expression upon sensitization.
MGL2
+DDCs incorporate FITC and accumulate in the
draining LNs within 24 h after FITC sensitization
Recent studies indicated that a migrant DC population loaded
with haptens reached the draining LNs earlier than LCs after CHS
sensitization [12,22]. The immigration of such migrant DCs
peaked between 24 to 48 h after sensitization, 2 or 3 days prior to
the migration of LCs [12,22]. Because of the absence of Langerin
expression and the incorporation of skin-painted haptens, it was
speculated that these migrant DCs were derived from the dermis.
However, resident DCs in LNs might also take up soluble antigens
drained directly to the LNs [11]. In addition, inflammatory
monocyte-derived DCs recruited to the skin or to the skin-draining
LNs from the blood upon skin inflammation were also potential
APCs in the skin-draining LNs [36–38]. Therefore, the presence of
hapten alone might not indicate that the cells were skin-derived.
To answer this question, we attempted to examine the antigen
uptake and time course of arrival of these cells in LNs using MGL2
as a marker for the DDC subset. First, incorporation of FITC into
MGL1
+ cells and MGL2
+ DDCs, both of which accumulate in the
Figure 2. Distribution of MGL2
+ cells in draining LNs during the sensitization with FITC revealed by immunohistochemical analysis.
(A) Serial sections of LNs stained with anti-MGL1, anti-MGL2 or anti-MGL1/2 cross-reactiv mAbs. MGL1 was strongly stained in the sinuses in both
naive and FITC sensitized (24 h after sensitization) LNs. Arrows indicate the increased signals in the cortex after the sensitization, though the anti-
MGL1 staining in the cortex was weaker than in the sinuses. Scale bar, 250 mm. (B) Serial LN sections 4 h after sensitization stained with mAbs to MØ/
DC markers. Restricted localization of MGL2
+ cells to the outer T cell cortex was unique compared to other APCs (MHCII) including B cells (B220), MØs
(CD11b and F4/80), DCs (CD11c) or MGL1
+ cells. S: subcapsular sinus, M: medulla, T: T cell cortex, B: B cell follicle. Scale bar, 200 mm. (C) Confocal
microscopic observations of the distributions of MGL1 (mAb LOM-8,7) or MGL2 (mAb URA-1) (blue in each panel) with MØ markers (red) in the LN
24 h after FITC sensitization. FITC used is shown in green. Scale bar, 25 mm( 6400).
doi:10.1371/journal.pone.0005619.g002
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PLoS ONE | www.plosone.org 5 May 2009 | Volume 4 | Issue 5 | e5619LNs 24 h after sensitization, was examined [25]. At 24 h after
sensitization, MGL2
+ DDCs as well as MGL1
+ cDCs, which
include the MGL2
+ DDC population (Figure 3B), were found to
contain FITC, while MGL1
+ pDCs did not (Figure 5A). The
proportion of MGL2
+ DDCs was about 10% among CD11c
+ DCs
in the naive LNs, and increased up to 50% on day 1, then
decreased to the steady state level by day 4 (Figure 5B). The
percentage of the FITC
+ MGL2
+ DDCs was the highest on day 1,
as was also the case with the total FITC
+ DC percentage in the
LNs, while the ratio of FITC
+ MGL2
2 DCs on day 1 was similar
to that on day 4, indicating that MGL2
+ DDCs migrated rapidly
compared to the MGL2
2 DCs (Figure 5B), consistent with the
non-LC migrants in previous reports [12,22]. The presence of
FITC (Figure 5) and the absence of Ly6G expression (Figure 3A)
in MGL2
+ DCs clarifies that MGL2
+ DCs are a distinct
population from inflammatory monocyte-derived DCs
[37,39,40]. These results suggest that MGL2
+ DDCs with antigens
arrived earlier at the draining LNs and were more likely to initiate
immune responses than LCs in CHS sensitization.
MGL2
+DDCs localize near the high endothelial venules in
naive and sensitized LNs
It was previously unknown whether LCs and DDCs had similar
spatial accessibility to naive T cells in the draining LNs. Because
MGL2
+ DDCs were found localized in the outer areas of the T cell
cortex under steady state conditions (Figure 2A and B), the
distribution of MGL2
+ DDCs and Langerin
+LCs within the LNs
was examined during the FITC sensitization period. As expected
Figure 3. Surface phenotype of MGL1
+ and MGL2
+ cells in naive peripheral LNs revealed by the flow cytometric analysis. (A) Surface
marker staining on cells gated on MGL1
+ or MGL2
+ populations in naive cutaneous LN. The gray peak in each panel indicates binding of rat IgG2a as a
negative control. (B) Double staining of anit-MGL1 and anti-MGL2 mAbs on the total LN cells (left) or MACS-purified CD11c
+ DCs (right). (C) Surface
staining by anti-MGL1 and anti-MGL2 mAbs on B220
+CD11c
int pDCs and B220
2 CD11c
+ cDCs. Each DC subset was gated as in the left panel. (D)
Intracellular staining of Langerin and surface staining of CD205 and MGL2 in MACS-purified CD11c
+ DCs. Langerin
+ and MGL2
+ cells were shown in
purple and orange respectively as gated in the left panel. (E) Flow cytometric analysis of the ratio of MGL2
+ DC (gated) in the naive and ADBP-treated
(24 h after the irritation) skins and LNs. Note that MGL2 signal was bright in all samples, suggesting that MGL2 expression was stable upon migration.
(F) Effect of PTX on the ratio of MGL2
+ DDC after FITC sensitization. The increase in the number of MGL2
+CD11c
+ DC induced by FITC (+FITC) was
significantly reduced (p,0.05) by concurrent administration of PTX with FITC painting (+FITC/PTX).
doi:10.1371/journal.pone.0005619.g003
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+ DDCs
were observed mainly in the outer T cell cortex, the T- and B-cell
boundaries, both in the draining and non-draining LN 24 h after
sensitization (Figure 6A). Interestingly, the MGL2
+ DDCs were
completely segregated from the Langerin
+ LCs, which were
scattered through the deep T cell cortex, indicating that the
distribution of these two DC subsets is distinct both under naive
and sensitized conditions. We also noted the presence of MGL2
2
Langerin
+ DCs loaded with very bright FITC, though their
number was relatively small (Figure 6A). They probably reflect the
presence of FITC
+ MGL2
2 Langerin
+ DCs detected by flow
cytometry in the draining LNs 24 h after sensitization (Figure 5B).
These cells might be Langerin
+ LCs reside in the LNs at the time
of sensitization and took up FITC in the LNs. They might also
represent Langerin
+ DDCs reported in Langerin-EGFP transgenic
mice [19–21].
The segregation of MGL2
+ DDCs and Langerin
+ LCs appeared
very similar to the distribution of the hapten-incorporated
Langerin
2 and Langerin
+ DCs reported previously [12], further
confirming each other that these cells were derived from the
dermis. In the LNs 24 h after sensitization, almost all the MGL2
+
DDCs were co-localized with FITC, indicating that MGL2
+
DDCs incorporated FITC at this time while only a few LCs
incorporated the hapten (Figure 6A). In addition, these FITC
+
MGL2
+ DDCs markedly accumulated around the venule-like
structures, and Langerin
+ LCs seemed to be relegated from these
areas at 24 h after sensitization (Figure 6A). To identify the
structures to which MGL2
+ DDCs accumulated in detail,
localizations of MGL2
+ DDCs, high endothelial venules (HEV),
LCs, and fibroreticular networks (FRN) in the LNs after
sensitization were examined. At all time points examined,
MGL2
+ DDCs localized close to peripheral lymph node addressin
(PNAd)
+ HEV. Some of the HEV were associated with ER-TR7
+
fibroreticular cells (Figure 6B) which were known to constitute an
HEV-associated fibroreticular network termed as cortical ridge
(CR) [41]. These results indicate that MGL2
+ DDCs distribute
around the CR regardless of the sensitization status, while
Langerin
+ LCs migrate further into the T cell cortex. Thus,
MGL2 is likely to serve as a specific marker for a subset of DDCs
and assists direct visualization of these cells in situ.
MGL2
+ DDCs are sufficient for induction of CHS
Because MGL2
+ DDCs apparently migrated and accumulated
in the CR, where DC-T cell interaction and initial proliferation of
antigen-specific T cells were known to take place [41,42], we
hypothesized that MGL2
+ DDCs alone are likely to initiate CHS
by presenting haptens to T cells. The availability of MGL2 as a
marker for a DDC subset enabled us to directly address whether
MGL2
+ DDCs were sufficient in the induction of CHS by
adoptive transfer experiments. FITC
+ MGL2
+ DDCs were
isolated from the draining LNs of FITC-painted mice at day 1,
and 7.5610
4 cells were transferred into the footpad of a naive
Figure 4. Expression of co-stimulatory molecules in MGL2
+ DDC revealed by the flow cytometric analysis. (A) CD40 and CD86 staining
on MGL2
+ DDC in naive cutaneous LNs. MACS-purified CD11c
+ DCs were sub-divided into MGL2
+ DDCs and MGL2
2 DCs (left panel). Populations I-III
indicate known cDC subsets in murine LNs. Note that MGL2
+ DDCs were exclusively assigned to population III (CD11c
hiCD40
hi DC). (B) Mean
fluorescent intensity of CD40 (filled bars) and CD86 (open bars) staining of MGL2
+ DDCs after FITC sensitization in the LN. *p,0.05, **p,0.00005.
Mean6SD obtained from three mice is shown.
doi:10.1371/journal.pone.0005619.g004
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PLoS ONE | www.plosone.org 8 May 2009 | Volume 4 | Issue 5 | e5619recipient (Figure 6). Six days later, the recall responses in the
recipients were elicited with FITC on the dorsal ear skin. Twenty-
four hours after FITC painting, a significant ear swelling in the
recipient of the MGL2
+ DDCs was observed to a similar extent to
the mice painted with FITC (Figure 7A). The swelling was
virtually absent when glutaraldehyde-fixed FITC
+ MGL2
+ DDCs
were transferred, suggesting that live cells were necessary to induce
CHS in this system (Figure 7A). As an additional control,
FITC
+MGL2
2DDCs isolated from the day 4 draining LNs were
tested. This time point was chosen because LC migration was
reported to peak around day 4 [12,22], though we could not
exactly address whether these transferred cells were LCs due to
low Langerin expression on the cell surfaces preventing us from
sorting experiments. When 5.0610
4 cells were transferred,
FITC
+MGL2
+DDCs isolated from the day 4 draining LNs were
able to induce CHS upon re-stimulation, whereas
FITC
+MGL2
2DCs, putatively LCs, were not (Figure 7B). Al-
though one could argue that the difference in CHS-inducing
capacity between these two populations were due to difference in
the efficiency of FITC incorporation and not to Ag-presentation
and/or migration capability, the results shown in Figure 7 strongly
suggest that MGL2
+DDCs are potent inducers of CHS. It is
possible that priming of T cells require participation of the third
subset, e.g. CD8
+DCs residing in LNs, as suggested by a previous
report [22]. Thus, whether MGL2
+DDCs alone are sufficient as
APCs remained to be examined in future studies. From our finding
that MGL2
+ DDCs were earlier migrants in CHS sensitization
and that they constituted the vast majority of the FITC-loaded
cells in the LNs at the early sensitization phase (Figure 5), we
concluded that expression of MGL2 is characteristic to a
migratory DC subset sufficient for inducing CHS.
Discussion
In the present study, selective expression of a C-type lectin,
MGL2, in the majority of DDCs was demonstrated. Using this as a
specific marker, the migration and the antigen presenting
functions of MGL2
+ DDCs in the initiation of CHS in the skin-
draining LNs became evident. Previously, the surface phenotype
differences between LCs and DDCs in cutaneous LNs were not
clear because definitions for these cells were based on the
anatomical comparison between cutaneous and mesenteric LNs
[7,10]. Only one molecule, Langerin, seemed to distinguish LCs
from DDCs, though this marker was also expressed in CD8a
+DCs
[3,43,44]. However, specificity of this marker to distinguish LCs
from DDCs in the skin-draining LNs was compromised by the
discovery of Langerin
+ DDCs [19–21].
In contrast to LCs, no marker has been identified for DDCs in
mouse. Until Langerin
+ DDCs were discovered, the DDCs in the
cutaneous LNs were distinguished from the LCs by their relatively
lower expression of CD205 and absence of Langerin [11,12]. It
was difficult to discriminate DDCs clearly from LCs, as both
CD205
hi and CD205
int fractions sorted from the LN-derived DCs
contained Langerin
+ and Langerin
2 DCs [12]. In addition,
because of similarity between LCs and DDCs, differential
expression of a particular marker between these two subsets was
debatable. For instance, when Langerin
+ LCs and Langerin
2
DDCs in the skin-draining LNs were compared for the expression
of CD11b, it was reported to be higher in Langerin
2 DDCs [45],
comparable in both DC subsets [11],or lower in DDCs [19]. Our
results demonstrated that MGL2
+DDCs in the skin-draining LNs
expressed higher levels of CD8a and CD11b than Langerin
+LCs
(data not shown). Identification of MGL2 as a specific marker for a
DDC subset enabled direct investigations of the phenotype and
function of DDCs in the skin-to-LN immune system.
We concluded that MGL2 could be utilized as a marker for a
DDC subset in skins and LNs based on the following observations.
First, in the skin, MGL2
+ cells represented the majority of dermal
MHCII
hi CD11c
+ cells. Second, MGL2
+ cells in LNs showed a
typical phenotype of interstitial DCs as reported previously
[6,7,9,10]. Third, MGL2
+ DCs in the LNs were populations
migrated from the skin and the migration was inhibited by PTX.
The expression of MGL2 was stable upon the migration. In
addition, judging from the immunohistochemistry and flow
cytometric analyses of LNs, MGL2
+ DDCs were a distinct
population from Langerin
+ LCs. The absence of Ly6G expression
and the FITC-loading capacity after CHS sensitization suggested
that MGL2
+ DDCs were also a distinct population from
inflammatory monocyte-derived DCs [37,39,40]. These results
confirmed that MGL2 was exclusively expressed in the majority of
the DDC subset (8867% in dermal CD11c
+MHCII
+cells as
shown in Figure 1C). We were not able to address whether
MGL2
+ DDCs were distinct from the Langerin
+ DDCs in the
physiological states, because the latter population was so far
distinguishable from Langerin
+ LCs only in bone marrow chimeric
mice [19–21]. However, we assume that the majority of MGL2
+
DDCs are distinct from Langerin
+ DDCs, based on the nearly
exclusive expression of MGL2 and Langerin in LNs by flow
cytometry (Figure 3D) and immunohistochemistry (Figure 6). In
organs other than the skin, MGL2
+ cells are present in other
stratified squamous epithelium of the mucosal lining of the vagina,
esophagus and oral cavity but not in the spleen (data not shown),
suggesting that MGL2 might be commonly expressed on a subset
of tissue-resident and migrant DCs with a similar developmental
background in each microenvironment. Although Mgl2 mRNA
transcription was reported to be upregulated in the alternative
activation of MØs [46], MGL2
+ DDCs seemed to be highly
immunogenic in vivo as demonstrated in the present study.
MGL2
+ DDCs were revealed to be early migrants from skins to
LNs in the CHS sensitization process, which accounted for the
appearance of hapten-loaded Langerin
2 DCs in the draining LNs
prior to LCs [12,14,22]. Thus, MGL2
+ DDCs but not LCs were
hypothesized to initiate adaptive immune responses to exogenous
antigens in the skin. LCs were classically believed to act as the
major APCs in CHS sensitization based on several findings [47]
including incorporation of antigens [48,49], correlation of CHS
response with LC density at the sensitization site [50], presence of
LCs with APC function in the LNs [15], and location of LCs at the
surface of the body [51]. In these previous reports, however,
identification of LCs was mainly based on the presence of the
Birbeck granules characterized by electron microscopy, which was
not applicable in studying cellular functions in situ. Some results
presented in these previous reports might be explained if the
Figure 5. Hapten incorporation and migration kinetics of MGL2
+ DDC after FITC sensitization revealed by the flow cytometric
analysis. (A) FITC fluorescence associated with MGL2
+ DDCs in LNs. MGL1
+ cDC (blue) or MGL2
+ DDCs (red), but not MGL1
+ pDCs (purple) or cells
nonspecifically bound by mAb URA-1 (orange) incorporate FITC. (B) Kinetics of MGL2
+ DDCs in LNs after FITC sensitization. Top panels indicate the
FITC fluorescence and staining with anti-MGL2 mAb on DCs purified from naive LNs (left) or LNs 24 h (middle) or 96 h (right) after sensitization. The
bottom panel shows the ratio of total FITC
+ DCs (closed diamond), FITC
+ MGL2
+ DDCs (open square) and FITC
+ MGL2
2 DCs (closed triangle)
calculated by each quadrant shown in top panels. The data are shown as Mean6SD.
doi:10.1371/journal.pone.0005619.g005
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et al. stated in their report that FITC incorporation was the highest
in LCs with Birbeck granules isolated from the LNs 24 h after
FITC sensitization [15], whereas the period is when MGL2
+
DDCs migrate into LNs in the present study. They also found that
the capability to proliferate T cells in vitro was the highest with
LCs isolated on day 1 but low with those isolated on day 4 [15].
However, our results, in conjunction with the results from the in
Figure 6. Immunohistochemical localization of MGL2
+ DDCs, LCs and LN conduits. (A) Distribution of MGL2 (red) and Langerin (blue) in a
draining (top) or a non-draining (bottom) LNs 24 h after FITC (green) sensitization. Arrows indicate venule-like structures in the CR. Arrowheads
indicate the Langerin
+ cells loaded with FITC. Almost all the MGL2
+ DDCs were FITC
+ and shown in yellow when merged. B: B cell follicles. Scale bar,
100 mm. (B) Distribution of MGL2 (red), PNAd (HEV), Langerin (LC) or ER-TR7 antigen (FRN) (blue in each panel) in the sensitization process. Areas
indicated by the squares are magnified in the lower panels. FITC is shown in green. CR associated with HEV in a naive LN is adjacent to MGL2
+ DDC
only at its follicular side but not at the cortical side. Arrowheads indicate association of MGL2
+ DDCs with ER-TR7
+ FRN around HEV-associated CR.
Scale bar, 100 mm.
doi:10.1371/journal.pone.0005619.g006
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the initiation of CHS [12,17,18]. These results suggest that
MGL2
+ DDCs but not LCs initiate adaptive immune responses to
antigens invading the skin.
In addition to the kinetics of the migration of MGL2
+ DDCs
from the dermis to the LNs, the unique localization of MGL2
+
DDCs within the LNs supports our hypothesis that MGL2
+ DDCs
are the predominant APCs in CHS. As reported previously [12],
the FITC
+MGL2
+ DDCs were segregated from the LCs in the
LNs 24 h after sensitization. Moreover, even in the steady state,
MGL2
+ DDCs were also physically and temporally separated from
the LCs and accumulated in the outer T cell cortex, especially in
the CR. This localization of MGL2
+ DDCs was found to be highly
unique among other DCs such as CD11c
+ DC, CD205
+ DCs and
Langerin
+ LCs, all of which were distributed throughout the T cell
cortex [1,52,53]. Two possibilities could explain the distinct
Figure 7. Induction of FITC-specific CHS in mice adoptively transferred with FITC
+ MGL2
+ DDC. (A) The left panels show the gating to
sort FITC
+ MGL2
+ cells from the MACS-purified CD11c
+ cells. The purity of FITC
+ MGL2
+ DDCs was approximately 98%. Ear swellings in mice
transferred with FITC
+ MGL2
+ DDCs (‘‘MGL2
+’’, p,0.005), transferred with glutaraldehyde-fixed FITC
+MGL2
+ DDC (‘‘fixed MGL2
+’’, difference not
statistically significant), sensitized directly with FITC painting (‘‘FITC painted’’, p,0.005), or untreated (‘‘naive’’) are shown in the graph. Each bar
indicates mean6SD obtained from three independent recipients respectively. (B) The left panels show the gating strategy to sort FITC
+MGL2
+DDCs
from the day 1 LNs or FITC
+MGL2
2DCs from the day 4 LNs. The purity of sorted cells was .90% when re-analyzed by FACS. Ear swelling in mice
transferred with 5610
4 cells of FITC
+MGL2
+DDCs from the day 1 LNs (d1 DDC), glutaraldehyde-fixed FITC
+MGL2
+DDCs from the day 1 LNs (fixed d1
DDC) or FITC
+MGL2
2DCs from the day 4 LNs (d4 non-DDC) is shown in the right panel. The mice sensitized by FITC painting (FITC painted) and left
untreated (naive) were used as positive and negative controls respectively. Each bar indicates the mean value from two recipients and the data are
representative of two independent experiments.
doi:10.1371/journal.pone.0005619.g007
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LCs migrate directly into the deep T cell cortex through different
lymphatics from the ones that MGL2
+ DDCs migrate through.
The other possibility is that these two migrants share the same
lymphatic routes to the LNs but are differently distributed within
the LNs. The former possibility is not likely because many HEVs
were surrounded by MGL2
+ DDCs at their follicular sides and by
the LCs at their cortical sides in naive LNs. It was likely that these
DCs once migrated to the same areas in the CR, and only LCs
migrated further into the deep T cell cortex while MGL2
+ DDCs
remained in the CR. The common route to the CR might be
under the regulation of the chemokine receptor CCR7 because
both CD11c
int CD40
hi DCs (population II in Figure 4A) and
CD11c
hi CD40
hi DCs (population III: MGL2
+ DDCs) seemed to
be reduced in the CCR7-deficient mice [35] and also because
CCR7 ligands might be concentrated on the CR stroma [41]. The
preferential localization of MGL2
+ DDCs in the CR is consistent
with the idea that MGL2
+ DDCs are the population responsible
for initiation of the CHS response because the CR is the sites of
interaction between DC and newly migrated T cells and the sites
of the primary T cell proliferation in vivo [41,42,54,55].
In conclusion, we have demonstrated that expression of MGL2
characterizes a DDC population sufficient for CHS initiation.
Functional difference between MGL2
+ DDCs and Langerin
+ DCs
in CHS and the molecular function of MGL2 in these cells should
further be characterized.
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